Reported Saturday, Vera Therapeutics Reveals 96-Week eGFR Stabilization In IgAN Patients with Atacicept: ORIGIN Phase 2b Study Findings Presented At ASN Kidney Week
Portfolio Pulse from Benzinga Newsdesk
Vera Therapeutics announced positive 96-week results from its ORIGIN Phase 2b study, showing eGFR stabilization in IgAN patients treated with atacicept. These findings suggest atacicept's potential in preventing kidney failure. The results were published in the Journal of the American Society of Nephrology, and an investor call is scheduled for October 28.
October 28, 2024 | 7:45 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Vera Therapeutics' ORIGIN Phase 2b study shows promising long-term results for atacicept in IgAN patients, indicating potential to prevent kidney failure. This could positively impact the company's stock as it highlights the drug's efficacy.
The positive long-term results from the ORIGIN Phase 2b study suggest that atacicept could be a significant treatment for IgAN, potentially leading to increased investor confidence and a positive impact on Vera Therapeutics' stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100